Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose, adaptive study of the efficacy of KL1333 in adult patients with primary mitochondrial disease

Next Previous
X
Search
Trial Profile

An interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose, adaptive study of the efficacy of KL1333 in adult patients with primary mitochondrial disease

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 23 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KL 1333 (Primary)
  • Indications Mitochondrial disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms FALCON
  • Sponsors Abliva

    • Most Recent Events

    • 18 Jul 2024 According to an Abliva media release, the independent Data Monitoring Committee (DMC) recommended continuing the study without modification.
    • 18 Jul 2024 According to an Abliva media release, the company plans to start the final wave of FALCON study recruitment in the second half of 2024.
    • 18 Jul 2024 Interim results presented in an Abliva Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top